Kindred Biosciences stock enters Elanco history after USD 440 million deal

Kindred Biosciences stock belongs to a completed transaction story: Elanco acquired the animal-health biotech for USD 440 million, and the deal closed on August 27, 2021. As of September 24, 2026, the central investor fact is the companys ownership status rather than a fresh standalone trading catalyst.

USD 440 million deal reshaped Kindred

Brands Owned By lists Kindred Biosciences among Elancos acquisitions at a deal value of USD 440 million in 2021. The transaction added pet therapeutics to Elancos animal-health portfolio and transferred Kindred into the larger groups operating structure.

The acquisition was announced on June 16, 2021, and the share price rose 46 percent after the announcement, according to Hannah Howell. That reaction shows how investors valued the transaction against the companys standalone market value before completion.

KIN is a historical ticker

The same account says the acquisition closed on August 27, 2021, making Kindred Biosciences a wholly owned Elanco subsidiary. For investors researching KIN, the date and ownership change are more important than treating the former ticker as an active independent equity story.

The USD 440 million purchase price and the 46 percent share-price reaction frame the deal from two angles: consideration paid by Elanco and the market response before closing. Together, those figures provide a concise reference for the final public phase of Kindred Biosciences.

Kindred Biosciences stock and ownership

Kindred Biosciences stock is best understood through the completed Elanco transaction. The companys public-market record ends with the August 27, 2021 closing date and the shift to wholly owned subsidiary status.